Talking Point Issue 38

Specialities with a strong business case Innovation and high quality are areas where we believe we stand out from our competitors. In this edition of Talking Point, we give some examples.

A series of fresh initiatives will drive our work in 2013, as we move towards the overall targets of our 2015 strategy. Following the completion of a major investment programme at Denmark Protein, we are now able to offer our customers new opportunities in speciality dairy-based ingredients.

In this we have two key priorities. The first is to demonstrate the value of  using innovative, whey based ingredients for both the food and nutrition industry. The second is to reinforce our emphasis on high product quality acknowledging that customer demand for quality will only become greater in the years to come.

Innovation and high quality are areas where we believe we stand out from our competitors. In this edition of Talking Point, we give some examples.

One of them is Lacprodan® HYDRO.365. Since its launch at Health Ingredients Europe 2012, this new whey protein hydrolysate for effective and palatable sports nutrition has attracted considerable market interest.

Another is our bioactive whey peptide Lacprodan® CGMP-20 targeting phenylketonuria (PKU) diets. Demand for this ingredient is such that we have now moved from pilot-scale to full-scale production in our extended production facilities in Denmark.This releases capacity to commence test production of other promising products we have in our innovation pipeline.

We look forward to continuing our dialogue with you during 2013, and you should expect more innovations from us throughout the year! 

On behalf of Arla Foods Ingredients, I wish you a very Happy New Year.

Henrik AndersenCEO